Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01114282
Recruitment Status : Completed
First Posted : May 3, 2010
Last Update Posted : July 6, 2016
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Michaela Liedtke, Stanford University

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : February 2014
  Study Completion Date : No date given